Correale et al. studied 41 metastatic CRC patients and found that patients with higher serum IL-4 levels had a longer overall survival when they receive the anticancer vaccine of thymidylate synthase poly-epitope-peptide [107]. The gene discussed is IL4; the disease is colorectal carcinoma.